Summary Background The burden of hepatitis C virus (HCV) infection is significant and is increasing with the aging population. The results of a modeling study that included Belgium, along with many other countries, was published in April 2014. An in depth discussion surrounding the epidemiology of HCV in Belgium will be presented here. Methods A […]
Summary No abstract available. Countries: Belgium Read the Full Report
Summary Background Chronic infection with hepatitis C virus (HCV) is a major cause of cirrhosis, hepatocellular carcinoma and liver transplantation. Objective To estimate the burden of HCV-related disease and costs from a Canadian perspective. Methods Using a system dynamic framework, the authors quantified the HCV-infected population, disease progression and costs in Canada between 1950 and […]
Summary The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis […]
Summary The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modeling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, […]
Summary Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For […]
Summary Chronic hepatitis C virus (HCV) infection leads to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The recent Global Burden of Disease project estimated that in 2010 among 170 million people living with chronic HCV, an estimated 483 100 people died from HCV-related liver failure or HCC. The last two decades has seen progressive improvements […]
Summary Collaborators New Paradigm of HCV Therapy Meeting Participants: Nezam H Afdhal, Rachel Baden, Cynthia Beam, Julie Krop, Clifford Brass, David Brumley, Laurent Castera, Daniel Church, Alfred DeMaria Jr, Kevin Cranston, Lynda Dee, Arnold Doyle, Julia Engstrom-Melnyk, Michael Fried, Camilla Graham, Michael Wong, William Guyer, John G McHutchison, Joe Steele, William Symonds, Ira M Jacobson, Alain Litwin, Anthony Martinez, Andrew Talal, Henry Masur, Douglas Mayers, Ronald C Renaud Jr, Shruti H Mehta, Andrew Muir, Christopher J Myatt, Stanley J Naides, Rick Pesano, William O’Brien, Christos J Petropoulos, Gastón R Picchio, Thierry […]
Summary The UNITAID 2013-2016 Strategy includes the treatment of HIV/AIDS and co-infections as one of six strategic objectives. This scoping report focuses on issues, challenges and opportunities related to one of the most important HIV co-infections—Hepatitis C virus (HCV)—and represents UNITAID’s first effort to gather market intelligence on products for the diagnosis and treatment of […]
Summary Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. A better understanding of HCV disease progression and the associated cost can help the medical community manage HCV and develop treatment strategies in light of the emergence of several potent anti-HCV therapies. A system dynamic model with 36 […]
English 
Spanish 
French 
Russian 
Arabic